Affimed N.V. (AFMDQ)

OTCMKTS · Delayed Price · Currency is USD
0.0514
-0.0243 (-32.08%)
At close: Jul 2, 2025
-99.05%
Market Cap 842.57K
Revenue (ttm) 6.29M
Net Income (ttm) -78.04M
Shares Out 16.39M
EPS (ttm) -5.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 269,217
Average Volume 135,211
Open 0.0710
Previous Close 0.0757
Day's Range 0.0506 - 0.0827
52-Week Range 0.0180 - 5.8400
Beta 1.97
RSI 33.42
Earnings Date Aug 8, 2025

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatme... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 76
Stock Exchange OTCMKTS
Ticker Symbol AFMDQ
Full Company Profile

Financial Performance

In 2023, Affimed's revenue was 13.91 million, a decrease of -67.39% compared to the previous year's 42.67 million. Losses were -105.94 million, 23.2% more than in 2022.

Financial numbers in EUR Financial Statements

News

There is no news available yet.